Back to Search Start Over

Refractory Pseudomonas aeruginosa Bronchopulmonary Infection After Lung Transplantation for Common Variable Immunodeficiency Despite Maximal Treatment Including IgM/IgA-Enriched Immunoglobulins and Bacteriophage Therapy.

Authors :
Levêque M
Cassir N
Mathias F
Fevre C
Daviet F
Bermudez J
Brioude G
Peyron F
Reynaud-Gaubert M
Coiffard B
Source :
Infection and drug resistance [Infect Drug Resist] 2023 Jun 30; Vol. 16, pp. 4265-4271. Date of Electronic Publication: 2023 Jun 30 (Print Publication: 2023).
Publication Year :
2023

Abstract

Recipients transplanted for bronchiectasis in the context of a primary immune deficiency, such as common variable immunodeficiency, are at a high risk of severe infection in post-transplantation leading to poorer long-term outcomes than other transplant indications. In this report, we present a fatal case due to chronic Pseudomonas aeruginosa bronchopulmonary infection in a lung transplant recipient with common variable immunodeficiency despite successful eradication of an extensively drug-resistant (XDR) strain with IgM/IgA-enriched immunoglobulins and bacteriophage therapy. The fatal evolution despite a drastic adaptation of the immunosuppressive regimen and the maximal antibiotic therapy strategy raises the question of the contraindication of lung transplantation in such a context of primary immunodeficiency.<br />Competing Interests: Dr Cindy Fevre reports personal fees from Pherecydes Pharma, outside the submitted work. The authors report no other conflicts of interest in this work.<br /> (© 2023 Levêque et al.)

Details

Language :
English
ISSN :
1178-6973
Volume :
16
Database :
MEDLINE
Journal :
Infection and drug resistance
Publication Type :
Report
Accession number :
37409241
Full Text :
https://doi.org/10.2147/IDR.S413900